The Valley Desk

NCT01318434 · Interventional trial

A Paroxetine- and Placebo-Controlled Study of 50 mg/Day and 100 mg/Day of EB-1010 Among Outpatients With Major Depressive Disorder Who Have Responded Inadequately to Prior Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin Norepinephrine Reuptake Inhibitors (SNRIs)

Overall registry status Completed

Phase 2 · Phase 3

Conditions Major Depressive Disorder

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov